Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony lekarski diagnoza białaczki włochatokomórkowej lub jej wariantu, która powróciła po poprzednim leczeniu
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia pozwalający na uczestnictwo w badaniu
- •Prawidłowa funkcja wątroby (poziom bilirubiny i enzymów poniżej określonych limitów)
- •Prawidłowa funkcja nerek (kreatynina poniżej 2,0 mg/dL lub klirens kreatyniny powyżej 45)
- •Pacjenci z HIV na skutecznym leczeniu z niewykrywalnym wirusem mogą uczestniczyć
- •Pacjenci z wirusem zapalenia wątroby B lub C muszą mieć kontrolowany stan zdrowia
- •Pacjenci nie otrzymujący wcześniej leku venetoclax
✗ Disqualifies
- •Leczenie białaczki w ciągu ostatnich 4 tygodni przed zapisem do badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (21)
City of Hope Comprehensive Cancer Center
Duarte, United States
City of Hope at Irvine Lennar
Irvine, United States
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, United States
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, United States
UM Sylvester Comprehensive Cancer Center at Coral Springs
Coral Springs, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, United States
UM Sylvester Comprehensive Cancer Center at Doral
Doral, United States
UM Sylvester Comprehensive Cancer Center at Hollywood
Hollywood, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, United States
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, United States
University of Kansas Cancer Center
Kansas City, United States
University of Kansas Cancer Center-Overland Park
Overland Park, United States
University of Kansas Hospital-Westwood Cancer Center
Westwood, United States
University of Maryland/Greenebaum Cancer Center
Baltimore, United States
NCI - Center for Cancer Research
Bethesda, United States
University of Kansas Cancer Center - Briarcliff
Kansas City, United States
University of Kansas Cancer Center - North
Kansas City, United States
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, United States
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Cincinnati Cancer Center-West Chester
West Chester, United States
Trial contact
Site Public Contact
Swetha Thiruvengadam
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Justin M. Watts
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Site Public Contact
Joseph Bennett
PRINCIPAL_INVESTIGATOR
Site Public Contact
Seung Tae Lee
PRINCIPAL_INVESTIGATOR
Site Public Contact
Robert J. Kreitman
PRINCIPAL_INVESTIGATOR
Site Public Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.